321970-54-1

Usage

Chemical class

Piperidine-based organic compound

Usage

Building block in the synthesis of pharmaceutical drugs and other organic compounds

Benzenesulfonyl

Provides nucleophilic sulfur for further functionalization

Piperidine ring

Confers structural stability and lipophilicity

Carboxylic acid

Allows for manipulation of the molecule's polarity and reactivity

Versatility

Valuable chemical intermediate with a wide range of potential applications in organic synthesis

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 498-95-3 nipecotic acid 

Downstream Products

• 1040877-93-7 1-benzenesulfonyl-piperidine-3-carboxylic acid methyl ester 
• 1188499-30-0 C₂₄H₂₀F₃N₅O₄S₂ 
• 1040880-25-8 2-(1-benzenesulfonyl-piperidin-3-yl)-N-methyl-N-piperidin-1-yl-acetamide 
• 1040878-91-8 2-(1-benzenesulfonyl-piperidin-3-yl)-N-piperidin-1-yl-acetamide 
• 1040880-59-8 C₁₃H₁₉NO₅S₂ 
• 1040877-98-2 (1-benzenesulfonyl-piperidin-3-yl)-acetic acid methyl ester 
• 1040878-00-9 (1-benzenesulfonyl-piperidin-3-yl)-acetic acid 
• 1040877-96-0 (1-benzenesulfonyl-piperidin-3-yl)-acetonitrile 
• 346691-49-4 (1-benzenesulfonyl-piperidin-3-yl)-methanol 

Relevant academic research and scientific papers

Design and synthesis of novel diamide derivatives of glycine as antihyperglycemic agents

DPP-4 inhibition is one of the most extensively explored approaches for the management of type 2 diabetes (T2D). Most DPP-4 inhibitors in the market contain a proline mimetic active pharmacophore. Herein, we report the design, synthesis, and preliminary e

PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1

The present invention relates to substituted piperidine compounds of the general formula (I) their tautomeric forms, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof. The invention also relates to process for the manufacture of said compounds, and pharmaceutical compositions containing them and their use.

N-substituted piperidines and their use as pharrmaceuticals

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.